198 related articles for article (PubMed ID: 36253784)
21. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy.
Abdel-Latif MM; O'Riordan J; Windle HJ; Carton E; Ravi N; Kelleher D; Reynolds JV
Ann Surg; 2004 Apr; 239(4):491-500. PubMed ID: 15024310
[TBL] [Abstract][Full Text] [Related]
22. Molecular biological challenges in he treatment of esophageal adenocarcinoma.
Boonstra JJ; Dinjens WN; Tilanus HW; Koppert LB
Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):275-86. PubMed ID: 19072420
[TBL] [Abstract][Full Text] [Related]
23. Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma.
Lynam-Lennon N; Bibby BA; Mongan AM; Marignol L; Paxton CN; Geiersbach K; Bronner MP; O'Sullivan J; Reynolds J; Maher SG
Mol Med; 2016 May; 22():388-97. PubMed ID: 27254108
[TBL] [Abstract][Full Text] [Related]
24. Metabolic tumor constitution is superior to tumor regression grading for evaluating response to neoadjuvant therapy of esophageal adenocarcinoma patients.
Buck A; Prade VM; Kunzke T; Feuchtinger A; Kröll D; Feith M; Dislich B; Balluff B; Langer R; Walch A
J Pathol; 2022 Feb; 256(2):202-213. PubMed ID: 34719782
[TBL] [Abstract][Full Text] [Related]
25. Immune Checkpoint Blockade and Targeted Therapies in Esophageal Cancer.
Yang J; Janjigian YY
Thorac Surg Clin; 2022 Nov; 32(4):467-478. PubMed ID: 36266034
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.
van den Ende T; Smyth E; Hulshof MCCM; van Laarhoven HWM
Best Pract Res Clin Gastroenterol; 2018; 36-37():45-52. PubMed ID: 30551856
[TBL] [Abstract][Full Text] [Related]
27. Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM; Chadwick JA; Owen RP; White MJ; Kaplinsky J; Peneva I; Frangou A; Xie PF; Chang J; Roth A; Amess B; James SA; Rei M; Fuchs HS; McCann KJ; Omiyale AO; Jacobs BA; Lord SR; Norris-Bulpitt S; Dobbie ST; Griffiths L; Ramirez KA; Ricciardi T; Macri MJ; Ryan A; Venhaus RR; Van den Eynde BJ; Karydis I; Schuster-Böckler B; Middleton MR; Lu X;
Cancer Cell; 2023 Jul; 41(7):1222-1241.e7. PubMed ID: 37433281
[TBL] [Abstract][Full Text] [Related]
28. The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma.
Sihag S; Nussenzweig SC; Walch HS; Hsu M; Tan KS; De La Torre S; Janjigian YY; Maron SB; Ku GY; Tang LH; Shah PM; Wu A; Jones DR; Solit DB; Schultz N; Ganesh K; Berger MF; Molena D
Clin Cancer Res; 2022 Jun; 28(12):2669-2678. PubMed ID: 35377946
[TBL] [Abstract][Full Text] [Related]
29. microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients.
Mari L; Hoefnagel SJM; Zito D; van de Meent M; van Endert P; Calpe S; Sancho Serra MDC; Heemskerk MHM; van Laarhoven HWM; Hulshof MCCM; Gisbertz SS; Medema JP; van Berge Henegouwen MI; Meijer SL; Bergman JJGHM; Milano F; Krishnadath KK
Gastroenterology; 2018 Sep; 155(3):784-798. PubMed ID: 29885883
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium.
Malhotra U; Zaidi AH; Kosovec JE; Kasi PM; Komatsu Y; Rotoloni CL; Davison JM; R C; Irvin ; Hoppo T; Nason KS; Kelly LA; Gibson MK; Jobe BA
PLoS One; 2013; 8(11):e78343. PubMed ID: 24223792
[TBL] [Abstract][Full Text] [Related]
31. Immunological Responses Associated With Neoadjuvant Therapy in the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma.
Takehara Y; Tamaki T; Mimura K; Saito K; Neupane P; Tada T; Watanabe Y; Hayase S; Saze Z; Yoshimoto Y; Sato H; Kono K; Suzuki Y
Anticancer Res; 2023 Oct; 43(10):4691-4700. PubMed ID: 37772585
[TBL] [Abstract][Full Text] [Related]
32. Integrating microarray-based spatial transcriptomics and single-cell RNA-sequencing reveals tissue architecture in esophageal squamous cell carcinoma.
Guo W; Zhou B; Yang Z; Liu X; Huai Q; Guo L; Xue X; Tan F; Li Y; Xue Q; Gao S; He J
EBioMedicine; 2022 Oct; 84():104281. PubMed ID: 36162205
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype.
Lynam-Lennon N; Heavey S; Sommerville G; Bibby BA; Ffrench B; Quinn J; Gasch C; O'Leary JJ; Gallagher MF; Reynolds JV; Maher SG
Oncotarget; 2017 Feb; 8(7):11400-11413. PubMed ID: 28002789
[TBL] [Abstract][Full Text] [Related]
34. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
[TBL] [Abstract][Full Text] [Related]
35. CD28/PD1 co-expression: dual impact on CD8
Palermo B; Franzese O; Frisullo G; D'Ambrosio L; Panetta M; Campo G; D'Andrea D; Sperduti I; De Nicola F; Goeman F; Gallina F; Visca P; Facciolo F; Nisticò P
J Exp Clin Cancer Res; 2023 Oct; 42(1):287. PubMed ID: 37898752
[TBL] [Abstract][Full Text] [Related]
36. Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes.
Jones JO; Smyth EC
Cancer Treat Rev; 2020 Mar; 84():101950. PubMed ID: 31918022
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis.
Ge F; Huo Z; Cai X; Hu Q; Chen W; Lin G; Zhong R; You Z; Wang R; Lu Y; Wang R; Huang Q; Zhang H; Song A; Li C; Wen Y; Jiang Y; Liang H; He J; Liang W; Liu J
JAMA Netw Open; 2022 Nov; 5(11):e2239778. PubMed ID: 36322089
[TBL] [Abstract][Full Text] [Related]
38. The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma.
Tsuchikawa T; Miyamoto M; Yamamura Y; Shichinohe T; Hirano S; Kondo S
Ann Surg Oncol; 2012 May; 19(5):1713-9. PubMed ID: 21822560
[TBL] [Abstract][Full Text] [Related]
39. Microarray-based response prediction in esophageal adenocarcinoma.
Schauer M; Janssen KP; Rimkus C; Raggi M; Feith M; Friess H; Theisen J
Clin Cancer Res; 2010 Jan; 16(1):330-7. PubMed ID: 20028767
[TBL] [Abstract][Full Text] [Related]
40. Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts.
Sharpe BP; Hayden A; Manousopoulou A; Cowie A; Walker RC; Harrington J; Izadi F; Breininger SP; Gibson J; Pickering O; Jaynes E; Kyle E; Saunders JH; Parsons SL; Ritchie AA; Clarke PA; Collier P; Mongan NP; Bates DO; Yacqub-Usman K; Garbis SD; Walters Z; Rose-Zerilli M; Grabowska AM; Underwood TJ
Cell Rep Med; 2022 Jun; 3(6):100541. PubMed ID: 35732148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
